KLADNÉ STANOVISKO CHMP PODPORUJE ŠIRŠÍ POUŽITÍ PŘÍPRAVKU REPATHA® SPOLEČNOSTI AMGEN PŘED PRVNÍM INFARKTEM NEBO MOZKOVOU MRTVICÍ
RegulatoryapprovedRepathaPositive
AI Analysis
Summary
Amgen's Repatha received a positive CHMP opinion supporting expanded use in primary prevention of myocardial infarction and stroke, based on Phase 3 trial data demonstrating significant cardiovascular risk reduction.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
CHMP positive opinion supporting broader use of Repatha in primary prevention
Importance:8/10
Sentiment:
0.85
PCSK9_inhibitorCardiovascularPrimary_PreventionCHMP_OpinionPhase_3Regulatory_Approval
Related Companies
Read the original article
Published by PR Newswire Biotech on July 31, 2026 4:20 PM